Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
about
Activation of rapid oestrogen signalling in aggressive human breast cancersDynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalkTargeting Src family kinases in anti-cancer therapies: turning promise into triumphA mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer modelInhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.An update on dual Src/Abl inhibitors.p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.Promising molecular targeted therapies in breast cancerLYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerDevelopment of a robust classifier for quality control of reverse-phase protein arrays.Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma.New insights on the role of hormonal therapy in ovarian cancerPreclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoInhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancerThe regulatory roles of phosphatases in cancer.Emerging strategies to overcome resistance to endocrine therapy for breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
P2860
Q24300885-0C5AAA8E-849D-4BD2-922D-ABE6A1209445Q26765201-45B5403D-F7B2-4981-AF38-D40584D31CCCQ27025646-1D345C22-01F2-4F6F-8EDB-600202CA9251Q30417300-F1D2DC33-0010-480E-AE18-1A61984F7D51Q30419413-89AB5EBE-D649-4064-8F5C-A43731210807Q30679405-4847F113-4D19-4C23-ABA0-C8F9B916123CQ33982322-C16CD053-B0BE-4BF5-B4C5-6713A80DC107Q34022694-306706A9-0C1C-49C7-B1EE-B6BFD4DC558FQ34051933-425F3A9C-38F8-476C-90B5-553A5020B4F2Q34270677-81470FA7-973E-4A95-9478-5FFA54C92689Q34472383-9C6A0B1D-4288-48A2-A86E-3D8B9D283E87Q35040295-A2A3224D-657A-49AE-BEFA-2C53230D9B9EQ35145443-64AF9967-42E5-4766-B2F8-B7501B867510Q35221345-0DDBA2CC-C97C-43A6-A8BD-802E062EE2B9Q35919052-FA6E1469-0501-4944-B2DC-19C6A6909D6AQ36001247-BA27C54D-527D-425A-9122-815B5422D7B9Q36245376-BDF7BB42-0153-45A5-B03C-6C1BEB76B1FCQ36586093-30DBB657-EF29-4AAF-99FC-7A5DC98350D3Q36974565-D62C9FCD-8485-41A3-A174-4CF4570B0CD3Q37240152-00AF8CF0-9F80-4FB0-84EB-6075AD20CEF9Q38090432-97D29DA3-64A0-49D9-9E5D-9ADBDFBF68F4Q38221463-91EBE3D7-5FC5-487E-9A4B-B9FC5E13C4B6Q38784119-E901B5B9-2E7D-4A22-80D3-80F8C7194730Q39160945-81A956A2-1642-4F47-8C1A-EBF19C5ED411Q50005441-4DCB2DEE-6867-4E4A-A4FA-4B498648C2CD
P2860
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@en
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@nl
type
label
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@en
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@nl
prefLabel
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@en
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@nl
P2093
P2860
P1476
Combined Src and ER blockade i ...... feration in vitro and in vivo.
@en
P2093
Bryan T Hennessy
Edwin A Alvarez
Joyce M Slingerland
Mercè Jordà
Natalia Guggisberg
Seth A Wander
Zhenlin Ju
P2860
P2888
P356
10.1007/S10549-010-1024-7
P407
P577
2010-07-29T00:00:00Z